Elidel, Protopic Get Boxed Warnings On Cancer, But Not At Top Of Labeling
Executive Summary
Boxed warnings about potential cancer risks will appear in the warning sections for Novartis' Elidel (pimecrolimus) and Astellas' Protopic (tacrolimus)
You may also be interested in...
Exelon Dementia Indication May Revive Flagging Sales, Novartis Says
Sales of Novartis' Alzheimer's disease therapy Exelon (rivastigmine tartrate) have taken a hit in the U.S. due to increased competition, the company said
Novartis To Maintain Sales Force In Face Of Potential Competitor Cutbacks
Novartis' decision to maintain its current sales force level could reflect the company's confidence in the continued growth of its pharmaceutical business
Elidel, Protopic “Black Box” Could Be Test Of FDA’s Labeling Authority
FDA's proposal to add a "black box" to labeling of the eczema treatments Elidel and Protopic could be a high-profile test of the agency's ability to change product labeling following recent congressional discussion of the agency's authority